Lenacapavir (Yeztugo) vs VH4004280 (VH-280)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Lenacapavir (Yeztugo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT04994509 · Phase 3 · active, not recruiting

This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.

Next expected readout: March 2027 · NCT07210125 (registry estimate)

Reported efficacy

Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)

Result source: NCT04925752

VH4004280 (VH-280)

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.

Reported efficacy

Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11); Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) (unclear)

Result source: NCT06039579

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointLenacapavir (Yeztugo)VH4004280 (VH-280)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT04925752—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT04925752—Not reported
CD4 count, change (week 48)—Trial running · NCT04925752—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Lenacapavir (Yeztugo)
—Trial running · NCT04925752
VH4004280 (VH-280)
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Lenacapavir (Yeztugo)
—Trial running · NCT04925752
VH4004280 (VH-280)
—Not reported

CD4 count, change (week 48)

Lenacapavir (Yeztugo)
—Trial running · NCT04925752
VH4004280 (VH-280)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lenacapavir (Yeztugo): 4 of 4 rows · VH4004280 (VH-280): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenacapavir (Yeztugo)VH4004280 (VH-280)
Dropout rate
11.5%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
94.4%
NCT04925752 · Phase 3 · combination · HIV · phase 3
0%Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
14.3%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Discontinued due to AEs
0.1%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.2%
NCT04925752 · Phase 3 · combination · HIV · phase 3
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—900 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—450 mg
NCT05163522 · Phase 1 · monotherapy
—350 mg
NCT05163522 · Phase 1 · monotherapy
—250 mg + Midazolam
NCT05163522 · Phase 1 · combination
—150 mg
NCT05163522 · Phase 1 · monotherapy
—100 mg
NCT05163522 · Phase 1 · monotherapy
—50 mg
NCT05163522 · Phase 1 · monotherapy
—10 mg
NCT05163522 · Phase 1 · monotherapy
Serious AEs
3.8%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
3.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 16 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%900 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%450 mg
NCT05163522 · Phase 1 · monotherapy
0%350 mg
NCT05163522 · Phase 1 · monotherapy
0%250 mg + Midazolam
NCT05163522 · Phase 1 · combination
0%150 mg
NCT05163522 · Phase 1 · monotherapy
0%100 mg
NCT05163522 · Phase 1 · monotherapy
0%50 mg
NCT05163522 · Phase 1 · monotherapy
0%10 mg
NCT05163522 · Phase 1 · monotherapy
Most frequent reported AEs
injection site nodule 66.1%
injection site pain 34.2%
genitourinary chlamydia infection 16.4%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
injection site nodule 63.4%
injection site pain 56.4%
injection site erythema 17.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Dose Level 1a
transaminases increased 16.7% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
arthralgia 0% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 16.7% (placebo 0%)
periodontitis 16.7% (placebo 0%)
rhinitis allergic 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
pyrexia 16.7% (placebo 0%)
thrombocytopenia 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
blood creatinine increased 33.3% (placebo 0%)
hypertriglyceridaemia 33.3% (placebo 0%)
cough 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
cough 16.7% (placebo 0%)
pharyngitis 16.7% (placebo 0%)
rhinitis 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
alanine aminotransferase increased 16.7% (placebo 0%)
dengue fever 16.7% (placebo 0%)
urticaria 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
900 mg
headache 16.7% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
450 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
450 mg
alanine aminotransferase increased 16.7% (placebo 10%)
amylase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 10%)
NCT05163522 · Phase 1 · monotherapy
350 mg
alanine aminotransferase increased 16.7% (placebo 10%)
aspartate aminotransferase increased 16.7% (placebo 10%)
bile acids increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
250 mg + Midazolam
fatigue 62.5% (placebo 0%)
blood creatine phosphokinase increased 25% (placebo 0%)
low density lipoprotein increased 25% (placebo 0%)
NCT05163522 · Phase 1 · combination
150 mg
abdominal discomfort 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 10%)
amylase increased 0% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
100 mg
dyslipidaemia 33.3% (placebo 0%)
bile acids increased 16.7% (placebo 0%)
blood bilirubin increased 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
50 mg
abdominal discomfort 28.6% (placebo 0%)
diarrhoea 28.6% (placebo 0%)
body temperature increased 14.3% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy
10 mg
chapped lips 16.7% (placebo 0%)
dermatitis contact 16.7% (placebo 10%)
dry mouth 16.7% (placebo 0%)
NCT05163522 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenacapavir (Yeztugo)

HIV-1 Incidence Per 100 PY 0 vs 2.018 F/TAF per 100 person year @ 52wk
event count · per 100 person year
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0 vs 2.018 F/TAF per 100 person year @ 52wk
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Per 100 PY 0 per 100 person year @ 52wk
event count · per 100 person year
No placebo or comparator arm
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 per 100 person year @ 149wk
event rate · per 100 person year
No placebo or comparator arm
NCT04925752 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.125 per 100 person year @ 149wk
NCT04925752 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 vs 0.931 F/TDF per 100 person year @ 149wk
event rate · per 100 person year
NCT04925752 · Phase 3 · combination · HIV · phase 3

VH4004280 (VH-280)

HIV-1 RNA -1.056 vs -0.07 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.391 vs -0.07 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.983 vs -0.07 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -0.941 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.322 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-1.939 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenacapavir (Yeztugo)'s landscape · VH4004280 (VH-280)'s landscape